The rate of the 6174delT founder Jewish mutation in
BRCA2 in patients with non-colonic gastrointestinal
tract tumours in Israel

A Figer1, L Irmin,1, R Geva,1 D Flex,1 J Sulkes,2 A Sulkes1 and E Friedman3

1Institute of Oncology and the Epidemiology Unit, Rabin Medical Center (Belinson Campus), Petach Tikva; 2 the Susanne Levy Gertner Oncogenetics Unit, Chaim Sheba Medical Center, Tel-Hashomer, 52621, and the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

Summary Inherited predisposition occurs in 5–10% of all gastrointestinal (GI) cancer patients, but with the exception of colorectal cancer (CRC), the genes involved in conferring genetic susceptibility remain largely unknown. Indirect evidence indicates that germline mutations in BRCA2 might be associated with an increased risk for various GI malignancies. A single mutation (6174delT) occurs in the BRCA2 gene in high-risk breast ovarian cancer families of Jewish Ashkenazi origin, in about 1% of the general Ashkenazi population, and rarely in non-Ashkenazi Jews. In order to assess the contribution of this germline mutation to non-CRC GI cancer in Jewish Israeli patients, we tested 70 unselected, consecutive Jewish Ashkenazi patients with gastrointestinal malignancies for this mutation by PCR amplification and modified restriction enzyme digests. Patients’ age range was 38–90 years (mean 65.8±11.8 years). The most common malignancies were gastric cancer (n = 35) and exocrine pancreatic cancer (n = 23). Overall, 6 mutation carriers were detected: 3/23 (13%) of the patients with pancreatic cancer, 2/35 (5.7%) of patients with gastric cancer and 1/4 (25%) of patients with bile duct cancer. The 8.6% mutation carrier rate among patients is a rate significantly higher than that of the general Ashkenazi population (1.16% P = 0.0002). We conclude that the rate of the predominant Jewish BRCA2 mutation in patients with gastric and pancreatic cancer significantly differ from that of the general population of the same ethnic origin. Thus, BRCA2 mutations probably contribute to gastrointestinal tumorigenesis other than colon cancer, and the surveillance scheme for mutation carriers should incorporate this information. © 2001 Cancer Research Campaign

Keywords: BRCA2; Jewish founder mutation; non-colon cancer; inherited predisposition to cancer

Gastrointestinal malignancies other than colorectal cancer (CRC) are common. In Israel in 1995, gastric cancer was diagnosed in 572 Jewish individuals, pancreatic cancer in 368, 140 were diagnosed with primary liver or biliary tract cancer, and 110 had oesophageal cancer (Israel Cancer Registry, 1998). Furthermore, the mortality rate from gastric and pancreatic cancer is high: in Israel the age stratified rate (ASR) for gastric cancer mortality is 10.9/100 000 in Jewish men and 5.6/100 000 in Jewish women, compared with an ASR for morbidity of 14.2/100 000 and 7.7/100 000, respectively (Israel Cancer Registry, 1998). This high mortality rate stems in part from the paucity of early symptoms and hence the advanced stage at which these neoplasms are usually diagnosed. Thus, identifying individuals at high risk for developing these malignancies has obvious clinical implications. Familial clustering of cancer, a well known risk factor predisposing to gastric, pancreatic, and other GI cancer is noted in 3–10% of all incident cases of these malignancies (Zanghieri et al, 1990; Lynch et al, 1992; Fernandez et al, 1994). The relative risk for developing gastric cancer in first-degree relatives of gastric cancer patients ranges from 1.7 to 3.5, with an increase in relative risk associated with having more than one affected family member (Zanghieri et al, 1990; Palli et al, 1994; Lissowska et al, 1999). Similarly, familial clustering of pancreatic cancer is associated with an increased risk for developing these neoplasms in all first degree relatives (Ghadirian et al, 1991; Lynch et al, 1992). These observations suggest an inherited predisposition to these cancer types in a subset of patients, but the genes that underlie this genetic susceptibility remain largely unknown. Clustering of ovarian and gastric cancer (Easton et al, 1996) and breast/ovarian and exocrine pancreatic cancer (Tulinius et al, 1992) have been reported, suggesting a role for BRCA2 gene mutations in pancreatic cancer predisposition (Phelel et al, 1996). Furthermore, a large study encompassing more than 3000 BRCA2 mutation carriers and their first-degree relatives, estimated the relative risk (RR) for developing cancers other than breast/ovarian: for pancreatic cancer the RR was 3.51, for gallbladder and bile duct cancer – 4.97 and for stomach cancer – 2.59 (BCLC, 1999).

Among Jewish people, a single predominant mutation within the BRCA2 gene (6174delT) occurs. This mutation can be detected in individuals at risk for developing breast and ovarian cancer (Abeliovich et al, 1997), in about 1–1.5% of the general Ashkenazi (East European) Jews (Ouddoux et al, 1996; Roa et al, 1996), and rarely among non-Ashkenazi Jews (Struweing et al, 1999). Analysis of 245 unselected patients with pancreatic cancer for this mutation, revealed two mutation carriers (0.8%) and an additional BRCA2 germline mutation carrier in a nearby codon (Goggins et al, 1996). However, not all patients in this latter study were Jewish individuals. Direct mutational analysis of 39 unselected Jewish Ashkenazi patients with pancreatic cancer, revealed 4 6174delT BRCA2 (10%) mutation carriers (Ozcelik et al, 1997).

To test the notion that BRCA2 mutations predispose to gastrointestinal malignancies other than colorectal cancer, we determined the rate of the BRCA2 6174delT predominant germline mutation in...
70 unselected Jewish Ashkenazi patients with these types of malignancies who were consecutively treated in a single medical centre in Israel.

**MATERIALS AND METHODS**

**Patients’ characteristics and tumour material**

All patients with a clinical and histopathological diagnosis of gastrointestinal malignancy (excluding colorectal cancer) who were treated at the Institute of Oncology, Rabin Medical Center from January 1, 1999 to March 31, 2000, were eligible for participation. The study was approved by the institutional review board, and all patients signed an informed consent. All consenting patients filled a detailed questionnaire that includes demographic data, past medical history, age at diagnosis, family history of cancer, especially gastrointestinal, breast and/or ovarian. Based on the criteria applied for other familial cancers, patients having at least one first-degree relative with GI or BRCA2 related cancer (breast and ovarian), or more than two second-degree relatives with cancer one of which is of GI, breast or ovarian origin, were classified as familial cases.

**DNA extraction**

Anticoagulated peripheral blood was withdrawn by venopuncture, and DNA was extracted using standard techniques, using the Gentra kit (Gentra Inc., Minneapolis, MN).

**Mutation analysis of the predominant Jewish mutation in BRCA2**

Mutational analyses for the predominant Jewish mutation (6174delT) in BRCA2, were carried out by restriction enzyme digest of amplified PCR products using modified amplification primers, to generate novel restriction sites, followed by restriction enzyme analysis to distinguish the mutant from the wild-type allele, as previously described (Rohlfs et al., 1997), and adopted by us (Bar Sade et al., 1998).

**Statistical analyses**

Comparison of the rates of the founder Jewish mutation in BRCA2 between the general Jewish Ashkenazi population (Hartage et al., 1999) and all GI cancer patients in our study group as well as the distribution within specific tumour types were performed using Fisher’s Exact test. Odds ratio (OR) and the 95% confidence intervals (CI) were calculated from the tables.

Even though the numbers for the Jewish Ashkenazi population are based on American Ashkenazi Jews (Hartage et al., 1999), we assumed that it is legitimate to use these numbers for two main reasons: first, the Ashkenazi Jewish population is well characterized as a distinct ethnic entity, regardless of the present place of residence (i.e. Tel-Aviv or Washington). Second, comparisons of Israeli and non-Israeli Ashkenazis with regard to being 185delAG BRCA1 mutation carriers, did not show any differences between Israelis and Americans (Streufing et al., 1997).

**RESULTS**

**Patients’ characteristics**

All 70 were of Ashkenazi origin. The most common malignancy was gastric cancer ($n = 35$), followed by exocrine pancreatic cancer ($n = 23$), oesophageal cancer ($n = 7$), bile duct cancer ($n = 4$) and one small bowel cancer. Median age at diagnosis was 67 years (range 38–90 years) with a mean age of 65.8±11.8 years; 6 patients (8.5%) were diagnosed between 38–49 years; 16 (22.8%) – between 50–59 years; 19 (27.2%) – between 60–69 years; 20 (28.6%) – between 70–79 years; 9 (12.8%) over the age of 80 years. 13 (18.5%) and 12 (17.1%) patients had first-degree relatives with gastrointestinal or other cancer, respectively, and 4 (5.7%) had at least one first-degree relative with breast cancer.

**Germline mutational analysis**

The presence of 6174delT BRCA2 germline mutation was tested in all study participants and 6 carriers were found (6/70–8.6%). The clinical and pertinent data of the 6 mutation carriers are presented in Table 1. Notably, 3/23 of the patients with pancreatic cancer (13%), 2/35 (5.7%) of the patients with gastric cancer and 1/4 of the patients (25%) with bile duct cancer were mutation carriers. Surprisingly, only 1/5 individuals with a family history of breast and/or ovarian cancer was among the mutation carriers, and family history of other cancer was ascertained in 4/6 mutation carriers (Table 1). In addition, the age at diagnosis in mutation carriers was not noticeably younger than other individuals with the same cancer type.

**Statistical analyses**

There was a statistically significant difference in the carrier rate of the 6174delT BRCA2 mutation between the general Jewish Ashkenazi population and all cancer types in the present study.

| Cancer type        | Mutation carriers | $P$ value | OR | CI   |
|--------------------|-------------------|-----------|----|------|
| Gastric            | 2/35 (5.7%)       | 0.06      | 5.2| 1.2–22|
| Pancreatic         | 3/23              | 0.002     | 12.8| 3.7–44.2|
| Bile duct          | 1/4               | 0.05      | 28.4| 2.9–277.2|
| Oesophageal        | 0/7               | NS        | –  | –    |
| Small intestine    | 0/1               | NS        | –  | –    |
| Total              | 6/70 (8.6%)       | 0.0002    | 8 | 3.3–19.2|

NS – denotes statistically not significant.

Table 1  Clinical and histopathological data of all BRCA2 mutation carriers in the present study

Table 2  Comparison between the mutation carrier rate of the predominant Jewish mutation in BRCA2 in the study population (Israeli Ashkenazi GI cancer patients) and the reference Jewish Ashkenazi population (from Hartage et al., 1999) by specific tumour types

© 2001 Cancer Research Campaign
combined (59/5089 vs. 6/70, P = 0.0002). Analysis of the rate of this mutation within specific tumour types, showed that the rates in pancreatic cancer and bile duct cancer were also statistically significant higher than population controls (Table 2).

DISCUSSION

In the present study, the involvement of the BRCA2 gene in inherited predisposition to gastrointestinal cancer other than colorectal cancer was evaluated by direct mutational analysis. The rate of the predominant Jewish mutation in BRCA2 in Ashkenazi patients with gastric, exocrine pancreatic cancer and bile duct cancer was significantly greater than the rate in the general Jewish Ashkenazi population (Struemwng et al., 1997; Hartage et al., 1999).

Furthermore, family history of cancer was elucidated in 4/6 mutation carriers, as an additional evidence that the mutation found is not merely an incidental finding, but rather reflects a true inherited predisposition.

The data presented herein are in agreement with other studies showing a higher than expected rate of BRCA2 gene germline mutations in pancreatic cancer in ethnically diverse populations, and in Ashkenazi Jews, in particular. The original observation regarding finding of 2/245 (0.8%) 6174delT mutation carriers and 4/39 (10%) among unselected patients (Goggins et al., 1996) or Jewish individuals (Ozellick et al., 1997) with pancreatic cancer has been mentioned. Analysis of 38 Jewish individuals with pancreatic cancer, revealed 3 (7.9%) BRCA2 6174delT mutation carriers (Lal et al., 2000). Furthermore, in Iceland, where a single predominant mutation (999del5) in BRCA2 exists, first-degree relatives of mutation carriers had a higher than expected rate of pancreatic cancer (Thorlacius et al., 1997). The role of BRCA2 mutations in conferring genetic susceptibility to gastric, oesophageal, hepatic and biliary tract cancer is much less established. A high rate of allelic loss at the BRCA2 locus has been reported, but few somatic mutations have been detected in BRCA2 in hepatocellular cancer (Katagiri et al., 1996). Similarly, 93% of oesophageal cancer from patients with a family history of the disease (n = 23), displayed allelic loss with a marker from the long arm of chromosome 13 (D13S894) (Hu et al., 1999). Moreover, in the most comprehensive study of cancer types other than breast and ovarian, associated with germline BRCA2 mutations, up to five-fold increased risk for biliary tract and more than double the risk for stomach cancer is reported (BCLC, 1999). However, to the best of our knowledge, no direct mutational analyses studies were ever performed in individuals with these latter cancer types.

The results of the present study which support other lines of indirect evidence as to the involvement of BRCA2 germline mutations in the susceptibility to cancer of the upper gastrointestinal tract, should be reflected in genetic counselling. The increased risk for developing these malignancies should be incorporated into the routine counselling process, and surveillance schemes aimed at early detection of these cancer types should be devised and tested. Furthermore, the subset of Ashkenazi Jewish patients with either gastric, pancreatic cancer or bile duct cancer and a strong family history of cancer should probably all be tested for being BRCA2 mutation carriers.

In conclusion, in Jewish individuals, germline mutations in the BRCA2 gene seem to contribute to the genetic susceptibility to gastric, exocrine pancreatic and/or biliary tract cancer, and a family history of these or related cancer types. The predictive value, penetrance and the lifetime risk for developing these neoplasms in Jewish BRCA2 mutation carriers remains to be determined in a larger, prospective study.

ACKNOWLEDGEMENT

This study was funded in part by generous donation from Mr Ami Ya’ar in loving memory of his late wife, Ruthi.

REFERENCES

Abeliovich D, Kaduri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Hechting N and Peretz T (1997) The founder mutation 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer among Ashkenazi women. Am J Hum Genet 60: 505–514

Bar-Sade RB, Kruglikova A, Modan B, Gak E, Hirsh-Yechzekel G, Theodor L, Novikov I, Gershoni-Baruch R, Risel S, Papa MZ, Ben-Baruch G and Friedman E (1998) The 185delAG BRCA1 mutation originated before the dispersion of Jews in the diaspora and is not limited to Ashkenazism. Hum Mol Genet 7: 801–805

Brest Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91: 1310–1316

Easton DF, Matthews FE, Ford D, Swerdlow AJ and Peto J (1996) Cancer mortality in relatives with ovarian cancer: the OPCS Study. Office of Population Censuses and Surveys. Int J Cancer 65: 284–294

Falk RT, Pickle LW, Fontham ET, Correa P and Fraumeni Jr FR (1998) Life-style risk factors for pancreatic cancer in Louisiana: a case-control study. Am J Epidemiol 128: 324–336

Fernandez E, La Vecchia C, D’Avanzo B, Negri E and Franceschi S (1994) Family history and the risk of liver, gallbladder, and pancreatic cancer. Cancer Epidemiol Biomarkers Prev 3: 209–212

Ghadriyan P, Boyle P, Simard A, Balilargonne J, Maisonneneuve P and Perret C (1991) Reported family aggregation of pancreatic cancer within a population-based case-control study in the Francophone community in Montreal, Canada. Int J Pancreatol 10: 183–196

Goggins M, Schute M, Lu J, Moskaluk CA, Weinstein CL, Petersen GM, Yeo CJ, Jackson CE, Lynch HT, Hruban RH and Kern SE (1996) Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 56: 5360–5364

Hartge P, Struemwng JP, Wacholder S, Brody LC and Tucker MA (1999) The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet 64: 963–970

Hu N, Roth MJ, Emmert-Buck MR, Tang ZZ, Polymeporolopus M, Wang QH, Goldstein AM, Han XY, Davseym SM, Ding T, Giffen C and Taylor PR (1999) Allelic loss in esophageal squamous cell carcinoma patients with and without family history of upper gastrointestinal tract cancer. Clin Cancer Res 5: 3476–3482

Israel Cancer Registry (1998) Cancer in Israel: facts and figures 1992–1995. Jerusalem: Ya’ar in loving memory of his late wife, Ruthi.

Lal G, Liu G, Schmocker B, Kaurah P, Ozelick H, Narod SA, Redston M and Gallagher S (2000) Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res 60: 409–416

Lissowska J, Groves FD, Sobin LH, Fraumeni JF Jr; Nasiwerska-Guttmejer A, Radziszewski J, Regula J, Hsing AW, Zatonski W, Blot WJ and Chow WH (1999) Family history and risk of stomach cancer in Warsaw, Poland. Eur J Cancer Prev 8: 223–227

Lynch HT, Fasuro L and Lynch JF (1992) Familial pancreatic cancer. A family study. Pancreatol 7: 511–515

Oddoux C, Struemwng JP, Clayton CM, Neuhausen S, Brody LC, Klaback Ma, Haas B, Norton L, Borgen P, Hjarward S, Gooldrad, D. Oster H and Offin K (1996) The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 14: 188–190

Ozelick H, Schmochner B, Di Nicola N, Shi XH, Langer B, Moore M, Taylor RR, Narod SA, Darlington G, ANDRULIS IL, Gallinger S and Redston M (1997) Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet 16: 17–18

Palli D, Galli M, Caporaso NE, Ciprini F, Decalfi A, Saieva C, Fraumeni JF Jr and Butiati E (1994) Family history and risk of stomach cancer in Italy. Cancer Epidemiol Biomarkers Prev 3: 15–18

British Journal of Cancer (2001) 84(4), 478–481 © 2001 Cancer Research Campaign
Phelan CM, Lancaster JM, Tonin P, Gumbs C, Cochran C, Carter R, Ghadirian P, Perret C, Moslchi R, Dion F, Faucher MC, Dole K, Karimi S, Foulkes W, Lounis H, Warner E, Goss P, Anderson D, Larsson C, Narod SA and Futreal PA (1996) Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. *Nat Genet* 13: 120–122

Roa BB, Boyd AA, Volick K and Richards CS (1996) Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. *Nat Genet* 14: 185–187

Rohlf EM, Learning WG, Friedman KJ, Couch FJ, Weber BL and Silverman LM (1997) Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA1 by PCR-mediated site-directed mutagenesis. *Clin Chem* 43: 24–29

Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC and Tucker MA (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. *N Engl J Med* 336: 1401–1408

Struewing JP, Coriaty ZM, Ron E, Livoff A, Konichezky M, Cohen P, Resnick MB, Lifschitz-Mrecrl B, Lew S and Iscovich J (1999) Founder BRCA1/2 mutations among male patients with breast cancer in Israel. *Am J Hum Genet* 65: 1800–1802

Thorlacius S, Sigurdsson S, Bjarnadottir H, Olafsdottir G, Jonasson JG, Tryggvadottir L, Tulinius H and Eyfjord JE (1997) Study of a single BRCA2 mutation with high carrier frequency in a small population. *Am J Hum Genet* 60: 1079–1084

Tulinius H, Egilsson V, Olafsdottir GH and Sigvaldason H (1992) Risk of prostate, ovarian and endometrial cancer among relatives of women with breast cancer. *Br Med J* 305: 855–857

Zanghieri G, Di Gregorio C, Sacchetti C, Fante R, Sassatelli R, Cannizzo G, Carriero A, Ponz de and Leon M (1990) Familial occurrence of gastric cancer in the 2-year experience of a population-based registry. *Cancer* 66: 2047–2051